Sai Life Sciences Q1 FY27: Growth holds up, while the platform expands beyond small molecules

Sai Life Sciences began FY27 with a steady quarter. Consolidated revenue from operations for Q1 FY27 (quarter ended 30 June 2026) came in at INR 554 crores, up 12 percent year-on-year. Profitability improved faster than revenue. EBITDA rose to INR 148 crores (27 percent margin), and profit after tax increased to INR 73 crores (13 percent margin).

Management framed the quarter as part of a longer transition. The company has historically been positioned as an integrated small-molecule CRDMO. In this update, leadership repeatedly described the next chapter as building a technology-led, multi-modality platform, with deeper strategic engagements and greater program ownership across discovery, development, and manufacturing.

Performance mix: CRO momentum offsets lumpiness in CDMO

The quarter’s growth was supported by both businesses, but the pace differed. Management stated that CDMO contributed about 60 percent of revenue in Q1 FY27 and CRO contributed the remaining 40 percent. On a year-on-year basis, the CRO business grew by about 26 percent, while CDMO grew by around 6 percent.

The CRO momentum aligns with the longer-term trend shown in the deck. Discovery services revenue has scaled consistently over multiple years, and the company highlighted increasing levels of integrated delivery, supported by investments in biology and DMPK alongside chemistry.

CDMO growth, by contrast, was described as inherently lumpy. Management again emphasized that quarterly performance depends on the timing of deliveries and purchase orders. They also reiterated an expectation that the second half of FY27 should be stronger than the first half, supported by capacity that is expected to come on stream by the end of Q2 or early Q3.

Financial summary (Consolidated)

Pipeline visibility and the FTE-led engagement strategy

A key management message through both the presentation and concall was pipeline durability. The investor deck stated over 90 percent pipeline visibility on FY27 targets. In the concall, management explained that dedicated FTE models are creating deeper relationships with customer development teams and strengthening the long-term funnel.

The CFO described three pipeline channels that are benefiting from this structure: molecules from biotech companies that Sai supported which are later acquired by pharma collaborators, molecules transferred to Sai when pharma companies acquire assets, and molecules from Sai’s own FTE relationships progressing into late-stage development.

On the CMC side, management cited 33 active commercial molecules and 14 late-phase molecules. They also said that over the last 15 months, six late-phase molecules were added, with five coming through large pharma customers with ongoing FTE engagements. One customer relationship was described as having expanded into an end-to-end collaboration spanning discovery to commercial.

The company also tied customer stickiness to repeat business. The CFO stated that returning customers accounted for over 90 percent of revenue in FY25 and FY26.

Capability build: peptides, conjugation, formulation, and advanced process technologies

Management’s strategic priorities for FY27 and beyond were concentrated around expanding the addressable scope of programs rather than only adding volume.

Peptides and new modalities

Peptides were called out as a major modality priority. Management said peptide demand goes beyond GLP-1s and referenced broader work in macrocyclic peptides and peptide-drug conjugates. They noted that a dedicated peptide development lab is coming online shortly for a top-tier pharma customer.

A larger step is planned at the new greenfield site near Hyderabad. Management said the company plans to break ground for a peptide manufacturing facility, expected to be operational in 2028. In the Q&A, the CFO provided a ballpark capex number for peptide initiatives, stating that total spend by the end of 2028 would likely be less than INR 300 crores.

The deck also showed that new modalities contributed 4 percent of revenue in FY26, after rising to 7 percent in FY25. Management indicated that new modalities work currently spans discovery and development, not commercial manufacturing.

XDC Center of Excellence

Management stated it is close to opening an XDC Center of Excellence, intended to support discovery and development teams in payload, linker synthesis and conjugation across antibodies, peptides, PROTACs and oligonucleotides. In Q&A, management added that pilot-scale conjugation space is already being built and that the footprint spans discovery and development work for ADCs.

Drug product (formulation) entry for early clinical supply

Another notable expansion is drug product capability. Management stated the company is entering formulation and will initially focus on small molecules, primarily oral solids, up to Phase 1 and Phase 2 clinical supplies. They clarified that this is not aimed at commercial supply at this stage.

The rationale was linked to customer demand. Management said partners are seeking China+1 options for early clinical materials, and that this offering works best when paired with an existing relationship on the development side.

Process technology and digital initiatives

On the technology front, the investor deck and concall referenced advanced process technologies such as flow chemistry and high-throughput experimentation. The company highlighted execution of commercial-scale photo flow chemistry for a late-phase innovator program and commissioning of an HTE platform at the Hyderabad R&D campus.

The deck also presented a structured digital roadmap. It stated that R&D and manufacturing are digitized to about 85 percent. Manufacturing digitization is expected to be complete by calendar year 2027. It also referenced an AI/ML manufacturing process prediction model, with proof-of-concept outcomes expected in calendar year 2026.

In the Q&A, the CFO clarified that HTE is not the same as AI. AI initiatives were described as targeting the elimination of non-value-add work currently performed by chemists and plant operators.

Capex and near-term outlook

The quarter included meaningful capital spending. The investor deck reported capex incurred of INR 263 crores in Q1. In the concall, the CFO reiterated FY27 capex guidance of INR 1,100 crores to INR 1,300 crores, and stated that the company has not provided FY28 guidance yet.

Capacity commissioning was positioned as a driver of a stronger second half. The CFO said that additional capacity is expected to come on stream by the end of Q2 or early Q3, which supports management’s expectation that H2 FY27 will be better than H1.

From a guidance standpoint, management reiterated its longer-term targets: 15 to 20 percent revenue growth over a three-to-five-year horizon and an EBITDA margin range of 28 to 30 percent. Q1 FY27 EBITDA margin was 27 percent, indicating that the company is not yet within the guided band for this quarter, even as it reiterated confidence in delivering the long-term range.

Closing takeaways

Sai Life Sciences delivered a steady start to FY27, with revenue growth of 12 percent and improving profitability. The CRO business continued to scale faster than CDMO in the quarter, while management emphasized the normal lumpiness of CDMO and pointed to a stronger H2 as capacity comes on stream.

The more important narrative is strategic. Management is pushing the business model toward deeper, FTE-led partnerships and a broader capability set. Peptides, conjugation (XDC), early clinical drug product, advanced process technologies, and a structured digital roadmap are central to that plan. If execution stays on track through the FY27 capex cycle, the company’s ambition to evolve from an integrated small-molecule CRDMO into a multi-modality partner will become easier to validate through the mix of programs and the durability of the pipeline.